Circulating Biomarkers for Diagnosis, Prognosis and Treatment Response Prediction in Cancer - Part B
- 1st Edition, Volume 398 - March 1, 2026
- Latest edition
- Editors: Lorenzo Galluzzi, Lorenzo Galluzzi, Sheila Spada
- Language: English
Circulating Biomarkers for Diagnosis, Prognosis and Treatment Response Prediction in Cancer Patients, Part B delves into the crucial role of circulating biomarkers in cancer diagno… Read more
Circulating Biomarkers for Diagnosis, Prognosis and Treatment Response Prediction in Cancer Patients, Part B delves into the crucial role of circulating biomarkers in cancer diagnosis and treatment monitoring. Specific chapters in this new release include Liquid biopsy approaches to capture minimal residual disease and therapy response in patients with early stage cancers, Identification of circulating biomarkers for cancer therapy-related cardiovascular toxicity, Extracellular Vesicles as Dynamic Biomarkers: Monitoring Therapeutic Responses and Drug Resistance in Cancer, and more.
This comprehensive work explores the various types of biomarkers, their significance in early cancer detection, prognostication, and evaluation of therapeutic responses. It covers cutting-edge research on circulating tumor cells, cell-free DNA, exosomes, and other biomarkers that can revolutionize cancer management. Additionally, it discusses the challenges, advancements, and future prospects of utilizing circulating biomarkers in personalized cancer care.
This comprehensive work explores the various types of biomarkers, their significance in early cancer detection, prognostication, and evaluation of therapeutic responses. It covers cutting-edge research on circulating tumor cells, cell-free DNA, exosomes, and other biomarkers that can revolutionize cancer management. Additionally, it discusses the challenges, advancements, and future prospects of utilizing circulating biomarkers in personalized cancer care.
- Provides a comprehensive overview of circulating biomarkers used in cancer diagnosis, prognosis, and treatment response monitoring
- Discusses the clinical utility of circulating biomarkers in early cancer detection, prognostication, treatment selection, and monitoring therapeutic responses
- Explores the latest technologies and methodologies for the detection, quantification, and analysis of circulating biomarkers in cancer patients
Oncologists and Cancer Researchers, Pathologists and Laboratory Professionals, Medical Libraries and Academic Institutions, Cancer Centers and Hospitals
1. Preface
Sheila Spada
2. Liquid biopsy approaches to capture minimal residual disease and therapy response in patients with early stage cancers
Valsamo Anagnostou, Blair Landon, Jinny Huang, Ellie Evangelopoulou and Jenna Canzoniero
3. Identification of circulating biomarkers for cancer therapy-related cardiovascular toxicity
Junjie Xiao, Junli Gao, Michail Spanos and Qiulian Zhou
4. title yet to decide
Fabio Grizzi
5. Extracellular Vesicles as Dynamic Biomarkers: Monitoring Therapeutic Responses and Drug Resistance in Cancer
Sherien M. El-Daly, Shaimaa Gouhar and Zakaria Abd Elmageed
6. Title yet to decide
Mulong Du
Sheila Spada
2. Liquid biopsy approaches to capture minimal residual disease and therapy response in patients with early stage cancers
Valsamo Anagnostou, Blair Landon, Jinny Huang, Ellie Evangelopoulou and Jenna Canzoniero
3. Identification of circulating biomarkers for cancer therapy-related cardiovascular toxicity
Junjie Xiao, Junli Gao, Michail Spanos and Qiulian Zhou
4. title yet to decide
Fabio Grizzi
5. Extracellular Vesicles as Dynamic Biomarkers: Monitoring Therapeutic Responses and Drug Resistance in Cancer
Sherien M. El-Daly, Shaimaa Gouhar and Zakaria Abd Elmageed
6. Title yet to decide
Mulong Du
- Edition: 1
- Latest edition
- Volume: 398
- Published: March 1, 2026
- Language: English
LG
Lorenzo Galluzzi
Lorenzo Galluzzi is Assistant Professor of Cell Biology in Radiation Oncology at the Department of Radiation Oncology of the Weill Cornell Medical College, Honorary Assistant Professor Adjunct with the Department of Dermatology of the Yale School of Medicine, Honorary Associate Professor with the Faculty of Medicine of the University of Paris, and Faculty Member with the Graduate School of Biomedical Sciences and Biotechnology of the University of Ferrara, the Graduate School of Pharmacological Sciences of the University of Padova, and the Graduate School of Network Oncology and Precision Medicine of the University of Rome “La Sapienza”. Moreover, he is Associate Director of the European Academy for Tumor Immunology and Founding Member of the European Research Institute for Integrated Cellular Pathology.
Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. He has published over 450 articles in international peer-reviewed journals and is the Editor-in-Chief of four journals:
OncoImmunology (which he co-founded in 2011), International Review of Cell and Molecular Biology, Methods in Cell biology, and Molecular and Cellular Oncology (which he co-founded in 2013). Additionally, he serves as Founding Editor for Microbial Cell and Cell Stress, and Associate Editor for Cell Death and Disease, Pharmacological Research and iScience.
Affiliations and expertise
Assistant Professor of Cell Biology in Radiation Oncology, Department of Radiation Oncology, Weill Cornell Medical College, NY, USALG
Lorenzo Galluzzi
Lorenzo Galluzzi is Assistant Professor of Cell Biology in Radiation Oncology at the Department of Radiation Oncology of the Weill Cornell Medical College, Honorary Assistant Professor Adjunct with the Department of Dermatology of the Yale School of Medicine, Honorary Associate Professor with the Faculty of Medicine of the University of Paris, and Faculty Member with the Graduate School of Biomedical Sciences and Biotechnology of the University of Ferrara, the Graduate School of Pharmacological Sciences of the University of Padova, and the Graduate School of Network Oncology and Precision Medicine of the University of Rome “La Sapienza”. Moreover, he is Associate Director of the European Academy for Tumor Immunology and Founding Member of the European Research Institute for Integrated Cellular Pathology.
Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. He has published over 450 articles in international peer-reviewed journals and is the Editor-in-Chief of four journals:
OncoImmunology (which he co-founded in 2011), International Review of Cell and Molecular Biology, Methods in Cell biology, and Molecular and Cellular Oncology (which he co-founded in 2013). Additionally, he serves as Founding Editor for Microbial Cell and Cell Stress, and Associate Editor for Cell Death and Disease, Pharmacological Research and iScience.
Affiliations and expertise
Assistant Professor of Cell Biology in Radiation Oncology, Department of Radiation Oncology, Weill Cornell Medical College, NY, USASS
Sheila Spada
Sheila Spada is at Weill Cornell Medical College, NY, USA
Affiliations and expertise
Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA